Photo taken from
Giannis Mountzios/X
Jun 2, 2024, 11:16
Giannis Mountzios: Lorlatinib in ALK positive NSCLC sets a new benchmark in Precision Oncology
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital, Athens, recently shared on X:
“For the 1st time in the history of Thoracic Oncology a molecular agent confers a median PFS exceeding 5 years in metastatic disease! Lorlatinib in ALK-positive NSCLC with the CROWN study sets a new benchmark in Precision Oncology!
Deserve to celebrate!”
Source: Giannis Mountzios/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56